Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Legal rebuff on parallel imports

Even as reimports are being touted as the way to undermine high pharmaceutical prices in the U.S., the concept of parallel imports came under attack last week in Europe from a high profile source: the advocate general of the European Court of Justice.

The advocate general, Francis Jacobs, issued an opinion challenging the EU Commission's prevailing concept that there is a free market for pharmaceuticals in the EU and that parallel trade should lead to lower drug

Read the full 773 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE